Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study.

Bergsland N, Ramasamy D, Tavazzi E, Hojnacki D, Weinstock-Guttman B, Zivadinov R.

AJNR Am J Neuroradiol. 2019 Apr;40(4):620-625. doi: 10.3174/ajnr.A6011. Epub 2019 Mar 14.

PMID:
30872420
2.

Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study.

Zivadinov R, Bergsland N, Carl E, Ramasamy DP, Hagemeier J, Dwyer MG, Lizarraga AA, Kolb C, Hojnacki D, Weinstock-Guttman B.

J Clin Med. 2019 Mar 12;8(3). pii: E344. doi: 10.3390/jcm8030344.

3.

Dalfampridine benefits ambulation but not cognition in multiple sclerosis.

Satchidanand N, Drake A, Smerbeck A, Hojnacki D, Kolb C, Patrick K, Weinstock-Guttman B, Motl R, Benedict RH.

Mult Scler. 2018 Dec 19:1352458518815795. doi: 10.1177/1352458518815795. [Epub ahead of print]

PMID:
30566030
4.

Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine.

Ghione E, Bergsland N, Dwyer MG, Hagemeier J, Jakimovski D, Paunkoski I, Ramasamy DP, Silva D, Carl E, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.

AJNR Am J Neuroradiol. 2018 Dec;39(12):2237-2242. doi: 10.3174/ajnr.A5876. Epub 2018 Nov 22.

PMID:
30467212
5.

Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study.

Jakimovski D, Gandhi S, Paunkoski I, Bergsland N, Hagemeier J, Ramasamy DP, Hojnacki D, Kolb C, Benedict RHB, Weinstock-Guttman B, Zivadinov R.

Eur J Neurol. 2019 Jan;26(1):87-e8. doi: 10.1111/ene.13769. Epub 2018 Sep 3.

PMID:
30103277
6.

Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis.

Zivadinov R, Tavazzi E, Bergsland N, Hagemeier J, Lin F, Dwyer MG, Carl E, Kolb C, Hojnacki D, Ramasamy D, Durfee J, Weinstock-Guttman B, Schweser F.

Radiology. 2018 Nov;289(2):487-496. doi: 10.1148/radiol.2018180136. Epub 2018 Jul 17.

PMID:
30015589
7.

The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study.

Zivadinov R, Tavazzi E, Hagemeier J, Carl E, Hojnacki D, Kolb C, Weinstock-Guttman B.

CNS Drugs. 2018 Aug;32(8):763-770. doi: 10.1007/s40263-018-0521-9.

PMID:
29767815
8.

Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures.

Zivadinov R, Bergsland N, Hagemeier J, Carl E, Kolb H, Hojnacki D, Weinstock-Guttman B.

J Neurol Sci. 2018 May 15;388:175-181. doi: 10.1016/j.jns.2018.03.028. Epub 2018 Mar 17.

PMID:
29627017
9.

Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study.

Zivadinov R, Bergsland N, Hagemeier J, Tavazzi E, Ramasamy DP, Durfee J, Cherneva M, Carl E, Carl J, Kolb C, Hojnacki D, Weinstock-Guttman B.

J Neurol Sci. 2018 Apr 15;387:152-156. doi: 10.1016/j.jns.2018.02.023. Epub 2018 Feb 10.

PMID:
29571854
10.

Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Postcontrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis.

Zivadinov R, Ramasamy DP, Hagemeier J, Kolb C, Bergsland N, Schweser F, Dwyer MG, Weinstock-Guttman B, Hojnacki D.

AJNR Am J Neuroradiol. 2018 Apr;39(4):642-647. doi: 10.3174/ajnr.A5541. Epub 2018 Feb 8.

11.

Fingolimod anti-inflammatory and neuroprotective effects modulation of RAGE axis in multiple sclerosis patients.

Sternberg Z, Kolb C, Chadha K, Nir A, Nir R, George R, Johnson J, Yu J, Hojnacki D.

Neuropharmacology. 2018 Mar 1;130:71-76. doi: 10.1016/j.neuropharm.2017.11.047. Epub 2017 Nov 29.

PMID:
29197515
12.

Ocrelizumab: a B-cell depleting therapy for multiple sclerosis.

Jakimovski D, Weinstock-Guttman B, Ramanathan M, Kolb C, Hojnacki D, Minagar A, Zivadinov R.

Expert Opin Biol Ther. 2017 Sep;17(9):1163-1172. doi: 10.1080/14712598.2017.1347632. Epub 2017 Jul 3. Review.

PMID:
28658986
13.

Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study.

Zivadinov R, Ramasamy DP, Vaneckova M, Gandhi S, Chandra A, Hagemeier J, Bergsland N, Polak P, Benedict RH, Hojnacki D, Weinstock-Guttman B.

Mult Scler. 2017 Sep;23(10):1336-1345. doi: 10.1177/1352458516678083. Epub 2016 Nov 4.

PMID:
27811339
14.

Use of natalizumab in multiple sclerosis: current perspectives.

Gandhi S, Jakimovski D, Ahmed R, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.

Expert Opin Biol Ther. 2016 Sep;16(9):1151-62. doi: 10.1080/14712598.2016.1213810. Epub 2016 Jul 27. Review.

PMID:
27413840
15.

Cerebral Microbleeds in Multiple Sclerosis Evaluated on Susceptibility-weighted Images and Quantitative Susceptibility Maps: A Case-Control Study.

Zivadinov R, Ramasamy DP, Benedict RR, Polak P, Hagemeier J, Magnano C, Dwyer MG, Bergsland N, Bertolino N, Weinstock-Guttman B, Kolb C, Hojnacki D, Utriainen D, Haacke EM, Schweser F.

Radiology. 2016 Dec;281(3):884-895. Epub 2016 Jun 16.

PMID:
27308776
16.

Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.

Zivadinov R, Hojnacki D, Bergsland N, Kennedy C, Hagemeier J, Melia R, Ramasamy DP, Durfee J, Carl E, Dwyer MG, Weinstock-Guttman B.

Eur J Neurol. 2016 Jun;23(6):1101-9. doi: 10.1111/ene.12992. Epub 2016 Mar 21.

PMID:
26998905
17.

Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.

Magner WJ, Weinstock-Guttman B, Rho M, Hojnacki D, Ghazi R, Ramanathan M, Tomasi TB.

J Neuroimmunol. 2016 Mar 15;292:68-78. doi: 10.1016/j.jneuroim.2016.01.009. Epub 2016 Jan 21.

18.

Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis.

Zivadinov R, Raj B, Ramanathan M, Teter B, Durfee J, Dwyer MG, Bergsland N, Kolb C, Hojnacki D, Benedict RH, Weinstock-Guttman B.

AJNR Am J Neuroradiol. 2016 Jun;37(6):1010-6. doi: 10.3174/ajnr.A4681. Epub 2016 Feb 18.

19.

Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation.

Weinstock-Guttman B, Hagemeier J, Kavak KS, Saini V, Patrick K, Ramasamy DP, Nadeem M, Carl E, Hojnacki D, Zivadinov R.

J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):937-43. doi: 10.1136/jnnp-2015-312221. Epub 2016 Jan 18.

PMID:
26780938
20.

Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS.

Tao Y, Zhang X, Zivadinov R, Dwyer MG, Kennedy C, Bergsland N, Ramasamy D, Durfee J, Hojnacki D, Hayward B, Dangond F, Weinstock-Guttman B, Markovic-Plese S.

Neurol Neuroimmunol Neuroinflamm. 2015 Nov 12;2(6):e176. doi: 10.1212/NXI.0000000000000176. eCollection 2015 Dec.

21.

Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.

Dwyer MG, Zivadinov R, Tao Y, Zhang X, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Weinstock-Guttman B, Hayward B, Dangond F, Markovic-Plese S.

BMC Neurol. 2015 Nov 11;15:232. doi: 10.1186/s12883-015-0488-9.

22.

Prior Asymptomatic Parenchymal Hemorrhage Does Not Increase the Risk for Intracranial Hemorrhage after Intravenous Thrombolysis.

AbdelRazek MA, Mowla A, Hojnacki D, Zimmer W, Elsadek R, Abdelhamid N, Elsadek L, Farooq S, Kamal H, Crumlish A, Shirani P, Ching M, Sawyer R.

Cerebrovasc Dis. 2015;40(5-6):201-4. doi: 10.1159/000439141. Epub 2015 Sep 25.

PMID:
26402147
23.

High-mobility group box 1 in multiple sclerosis.

Sternberg Z, Sternberg D, Chichelli T, Drake A, Patel N, Kolb C, Chadha K, Yu J, Hojnacki D.

Immunol Res. 2016 Apr;64(2):385-91. doi: 10.1007/s12026-015-8673-x.

PMID:
26100980
24.

Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis.

Kappus N, Weinstock-Guttman B, Hagemeier J, Kennedy C, Melia R, Carl E, Ramasamy DP, Cherneva M, Durfee J, Bergsland N, Dwyer MG, Kolb C, Hojnacki D, Ramanathan M, Zivadinov R.

J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):181-7. doi: 10.1136/jnnp-2014-310051. Epub 2015 Feb 26.

PMID:
25722366
25.

Disease modifying drugs modulate endogenous secretory receptor for advanced glycation end-products, a new biomarker of clinical relapse in multiple sclerosis.

Sternberg Z, Sternberg D, Drake A, Chichelli T, Yu J, Hojnacki D.

J Neuroimmunol. 2014 Sep 15;274(1-2):197-201. doi: 10.1016/j.jneuroim.2014.07.005. Epub 2014 Jul 15.

PMID:
25064498
26.

Prospective randomized trial of venous angioplasty in MS (PREMiSe).

Siddiqui AH, Zivadinov R, Benedict RH, Karmon Y, Yu J, Hartney ML, Marr KL, Valnarov V, Kennedy CL, Ramanathan M, Ramasamy DP, Dolic K, Hojnacki DW, Carl E, Levy EI, Hopkins LN, Weinstock-Guttman B.

Neurology. 2014 Jul 29;83(5):441-9. doi: 10.1212/WNL.0000000000000638. Epub 2014 Jun 27. Erratum in: Neurology. 2014 Aug 19;83(8):773.

27.

Characterizing cognitive function during relapse in multiple sclerosis.

Benedict RH, Morrow S, Rodgers J, Hojnacki D, Bucello MA, Zivadinov R, Weinstock-Guttman B.

Mult Scler. 2014 Nov;20(13):1745-52. doi: 10.1177/1352458514533229. Epub 2014 May 19.

PMID:
24842959
28.

Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study.

Zivadinov R, Dwyer MG, Markovic-Plese S, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Hayward B, Dangond F, Weinstock-Guttman B.

PLoS One. 2014 Mar 13;9(3):e91098. doi: 10.1371/journal.pone.0091098. eCollection 2014.

29.

Quantitative and qualitative pleiotropic differences between Simvastatin single and Vytorin combination therapy in hypercholesterolemic subjects.

Sternberg Z, Chichelli T, Sternberg D, Hojnacki D, Drake A, Liu S, Hu Q, Munschauer F.

Atherosclerosis. 2013 Dec;231(2):411-20. doi: 10.1016/j.atherosclerosis.2013.09.031. Epub 2013 Oct 16.

PMID:
24267260
30.

Aqueductal cerebrospinal fluid pulsatility in healthy individuals is affected by impaired cerebral venous outflow.

Beggs CB, Magnano C, Shepherd SJ, Marr K, Valnarov V, Hojnacki D, Bergsland N, Belov P, Grisafi S, Dwyer MG, Carl E, Weinstock-Guttman B, Zivadinov R.

J Magn Reson Imaging. 2014 Nov;40(5):1215-22. doi: 10.1002/jmri.24468. Epub 2013 Nov 8.

PMID:
24214844
31.

Multimodal noninvasive and invasive imaging of extracranial venous abnormalities indicative of CCSVI: results of the PREMiSe pilot study.

Zivadinov R, Karmon Y, Dolic K, Hagemeier J, Marr K, Valnarov V, Kennedy CL, Hojnacki D, Carl EM, Hopkins LN, Levy EI, Weinstock-Guttman B, Siddiqui AH.

BMC Neurol. 2013 Oct 20;13:151. doi: 10.1186/1471-2377-13-151.

32.

Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis.

Sternberg Z, Leung C, Sternberg D, Yu J, Hojnacki D.

Cardiovasc Ther. 2014 Apr;32(2):33-9. doi: 10.1111/1755-5922.12049.

PMID:
24119301
33.

Comparison of intravascular ultrasound with conventional venography for detection of extracranial venous abnormalities indicative of chronic cerebrospinal venous insufficiency.

Karmon Y, Zivadinov R, Weinstock-Guttman B, Marr K, Valnarov V, Dolic K, Kennedy CL, Hojnacki D, Carl EM, Hagemeier J, Hopkins LN, Levy EI, Siddiqui AH.

J Vasc Interv Radiol. 2013 Oct;24(10):1487-98.e1. doi: 10.1016/j.jvir.2013.06.012. Epub 2013 Aug 14.

PMID:
23953830
34.

Prevalence of radiologically isolated syndrome and white matter signal abnormalities in healthy relatives of patients with multiple sclerosis.

Gabelic T, Ramasamy DP, Weinstock-Guttman B, Hagemeier J, Kennedy C, Melia R, Hojnacki D, Ramanathan M, Zivadinov R.

AJNR Am J Neuroradiol. 2014 Jan;35(1):106-12. doi: 10.3174/ajnr.A3653. Epub 2013 Jul 25.

35.

Chronic cerebrospinal venous insufficiency is not associated with cognitive impairment in multiple sclerosis.

Benedict RH, Weinstock-Guttmam B, Marr K, Valnarov V, Kennedy C, Carl E, Brooks C, Hojnacki D, Zivadinov R.

BMC Med. 2013 Jul 18;11:167. doi: 10.1186/1741-7015-11-167.

36.

Changes of cine cerebrospinal fluid dynamics in patients with multiple sclerosis treated with percutaneous transluminal angioplasty: a case-control study.

Zivadinov R, Magnano C, Galeotti R, Schirda C, Menegatti E, Weinstock-Guttman B, Marr K, Bartolomei I, Hagemeier J, Malagoni AM, Hojnacki D, Kennedy C, Carl E, Beggs C, Salvi F, Zamboni P.

J Vasc Interv Radiol. 2013 Jun;24(6):829-38. doi: 10.1016/j.jvir.2013.01.490. Epub 2013 Mar 21.

PMID:
23523158
37.

MRI characteristics of familial and sporadic multiple sclerosis patients.

Tipirneni A, Weinstock-Guttman B, Ramanathan M, Abdelrahman N, Hussein S, Hagemeier J, Durfee J, Teter BE, Hojnacki D, Dwyer MG, Zivadinov R.

Mult Scler. 2013 Aug;19(9):1145-52. doi: 10.1177/1352458512469697. Epub 2012 Dec 11.

PMID:
23232600
38.

Heart disease, overweight, and cigarette smoking are associated with increased prevalence of extra-cranial venous abnormalities.

Dolic K, Weinstock-Guttman B, Marr K, Valnarov V, Carl E, Hagemeier J, Kennedy C, Kilanowski C, Hojnacki D, Ramanathan M, Zivadinov R.

Neurol Res. 2012 Oct;34(8):819-27. doi: 10.1179/1743132812Y.0000000062.

PMID:
22971471
39.

Comparison of standard 1.5 T vs. 3 T optimized protocols in patients treated with glatiramer acetate. A serial MRI pilot study.

Zivadinov R, Hojnacki D, Hussein S, Bergsland N, Carl E, Durfee J, Dwyer MG, Kennedy C, Weinstock-Guttman B.

Int J Mol Sci. 2012;13(5):5659-73. doi: 10.3390/ijms13055659. Epub 2012 May 10.

40.

Cine cerebrospinal fluid imaging in multiple sclerosis.

Magnano C, Schirda C, Weinstock-Guttman B, Wack DS, Lindzen E, Hojnacki D, Bergsland N, Kennedy C, Belov P, Dwyer MG, Poloni GU, Beggs CB, Zivadinov R.

J Magn Reson Imaging. 2012 Oct;36(4):825-34. doi: 10.1002/jmri.23730. Epub 2012 Jun 25.

PMID:
22733409
41.

Limb ataxia originating from peri-central sulcus demyelinating lesion in multiple sclerosis.

Karmon Y, Morrow SA, Weinstock A, Hojnacki D, Weinstock-Guttman B.

J Neurol Sci. 2012 Sep 15;320(1-2):136-40. doi: 10.1016/j.jns.2012.05.039. Epub 2012 Jun 12.

PMID:
22698481
42.

Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis.

Weinstock-Guttman B, Ramanathan M, Marr K, Hojnacki D, Benedict RH, Morgan C, Yeh EA, Carl E, Kennedy C, Reuther J, Brooks C, Hunt K, Elfadil M, Andrews M, Zivadinov R.

BMC Neurol. 2012 May 15;12:26. doi: 10.1186/1471-2377-12-26.

43.

No association between conventional brain MR imaging and chronic cerebrospinal venous insufficiency in multiple sclerosis.

Zivadinov R, Cutter G, Marr K, Ramanathan M, Benedict RH, Bergsland N, Morgan C, Carl E, Hojnacki D, Yeh EA, Willis L, Cherneva M, Kennedy C, Dwyer MG, Weinstock-Guttman B.

AJNR Am J Neuroradiol. 2012 Nov;33(10):1913-7. doi: 10.3174/ajnr.A3112. Epub 2012 May 10.

44.

Comparison of a 1.5T standard vs. 3T optimized protocols in multiple sclerosis patients.

Livshits I, Hussein S, Kennedy C, Weinstock-Guttman B, Hojnacki D, Zivadinov R.

Minerva Med. 2012 Apr;103(2):97-102.

PMID:
22513514
45.

Iron deposition on SWI-filtered phase in the subcortical deep gray matter of patients with clinically isolated syndrome may precede structure-specific atrophy.

Hagemeier J, Weinstock-Guttman B, Bergsland N, Heininen-Brown M, Carl E, Kennedy C, Magnano C, Hojnacki D, Dwyer MG, Zivadinov R.

AJNR Am J Neuroradiol. 2012 Sep;33(8):1596-601. doi: 10.3174/ajnr.A3030. Epub 2012 Mar 29.

46.

Sensitivity and specificity for screening of chronic cerebrospinal venous insufficiency using a multimodal non-invasive imaging approach in patients with multiple sclerosis.

Dolic K, Marr K, Valnarov V, Dwyer MG, Carl E, Hagemeier J, Kennedy C, Brooks C, Kilanowski C, Hunt K, Hojnacki D, Weinstock-Guttman B, Zivadinov R.

Funct Neurol. 2011 Oct-Dec;26(4):205-14.

47.

Lp-PLA2: inflammatory biomarker of vascular risk in multiple sclerosis.

Sternberg Z, Drake A, Sternberg DS, Benedict RH, Li F, Hojnacki D, Weinstock-Guttmann B, Munschauer FE.

J Clin Immunol. 2012 Jun;32(3):497-504. doi: 10.1007/s10875-011-9642-3. Epub 2012 Jan 13.

PMID:
22246459
48.

Intra- and extraluminal structural and functional venous anomalies in multiple sclerosis, as evidenced by 2 noninvasive imaging techniques.

Dolic K, Marr K, Valnarov V, Dwyer MG, Carl E, Karmon Y, Kennedy C, Brooks C, Kilanowski C, Hunt K, Siddiqui AH, Hojnacki D, Weinstock-Guttman B, Zivadinov R.

AJNR Am J Neuroradiol. 2012 Jan;33(1):16-23. doi: 10.3174/ajnr.A2877. Epub 2011 Dec 22.

49.

Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.

Zivadinov R, Dwyer MG, Hussein S, Carl E, Kennedy C, Andrews M, Hojnacki D, Heininen-Brown M, Willis L, Cherneva M, Bergsland N, Weinstock-Guttman B.

Mult Scler. 2012 Aug;18(8):1125-34. doi: 10.1177/1352458511433304. Epub 2011 Dec 22.

PMID:
22194217
50.

Risk factors for chronic cerebrospinal venous insufficiency (CCSVI) in a large cohort of volunteers.

Dolic K, Weinstock-Guttman B, Marr K, Valnarov V, Carl E, Hagemeier J, Brooks C, Kilanowski C, Hojnacki D, Ramanathan M, Zivadinov R.

PLoS One. 2011;6(11):e28062. doi: 10.1371/journal.pone.0028062. Epub 2011 Nov 30.

Supplemental Content

Loading ...
Support Center